Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• High-grade serous ovarian cancer (HGSOC) often develops resistance to platinum and taxane chemotherapy.
• Aurora A kinase (AAK), crucial for G2-M cell cycle transition, is implicated in cancer progression and drug resistance.

Purpose of the Study:

• To investigate if inhibiting AAK enhances the anti-tumor efficacy of cisplatin (CP) or paclitaxel (PT) in platinum-taxane resistant HGSOC.
• To evaluate the combination therapy in HGSOC cell lines lacking BRCA1/2 mutations.

Main Methods:

• HGSOC cell lines from refractory patients were treated with CP or PT alone, or sequentially with the AAK inhibitor alisertib (AL).
• Cell survival, reactive oxygen species production, apoptosis, and cell cycle progression were assessed.
• AAK and Aurora B kinase (ABK) were downregulated using siRNAs to confirm target specificity.

Main Results:

• Sequential treatment with CP or PT followed by AL significantly reduced HGSOC cell survival compared to monotherapy (p < 0.001).
• The combination therapy increased reactive oxygen species (p < 0.05) and apoptosis (p < 0.001), inducing G2/M cell cycle arrest.
• AAK inhibition via siRNA also enhanced CP or PT-induced apoptosis, confirming AL's specific targeting of AAK.

Conclusions:

• Sequential administration of alisertib with cisplatin or paclitaxel can circumvent platinum-taxane resistance in HGSOC lacking BRCA1/2 mutations.
• Targeting AAK represents a promising strategy to enhance chemotherapy effectiveness in refractory ovarian cancer.